Theravance Biopharma v. Qilu Pharmaceutical: Consent Judgment in 97 Days
Theravance Biopharma R&D IP, LLC filed suit in the Western District of Pennsylvania against Qilu Pharmaceutical Co., Ltd. asserting seven patents covering YUPELRI® (revefenacin) inhalation solution. The case resolved in just 97 days via a stipulated consent judgment and injunction — a resolution pace that strongly suggests pre-litigation negotiation or an agreed market-entry timeline.
Seven-patent YUPELRI® enforcement resolved by agreed injunction
On June 18, 2024, Theravance Biopharma R&D IP, LLC filed a patent infringement action in the U.S. District Court for the Western District of Pennsylvania (Case No. 2:24-cv-02689) against Qilu Pharmaceutical Co., Ltd., a Chinese generic drug manufacturer. The complaint asserted seven U.S. patents — US8541451B2, US11008289B2, US9765028B2, US11858898B2, US11691948B2, US10550081B2, and US11484531B2 — all directed to revefenacin, the active ingredient in YUPELRI®, a once-daily nebulized muscarinic antagonist approved for COPD maintenance treatment.
The case closed on September 23, 2024, when the parties entered a stipulated consent judgment and injunction. This mechanism — a court-entered order reflecting the parties’ agreement — carries the force of a judicial judgment while reflecting negotiated terms. The injunction component suggests Qilu accepted restrictions on U.S. market entry for its revefenacin product, at least for a defined period. The basis of termination is recorded as ‘Case Dismissed,’ consistent with the case being resolved by consent rather than contested litigation.
A 97-day resolution is notably fast for a seven-patent pharmaceutical infringement action, suggesting that substantive negotiations were either underway before filing or reached quickly after service. The public record does not disclose whether the consent judgment includes a licensed entry date, royalty terms, or any carve-outs. What is clear is that Theravance secured an injunction without contested merits proceedings — a commercially significant outcome for a branded COPD product with ongoing patent protection extending into the 2030s.
Filing to Case Dismissed in 97 days
97 days — well below the median district court patent case duration of ~2.5 years
Consent judgment and injunction: what the agreed order means for both parties
Stipulated consent judgment carries full judicial force
A stipulated consent judgment is not merely a settlement agreement — it is a court-entered order that binds the parties with the authority of a judicial ruling. Once entered, it is enforceable through contempt proceedings. Here, the order also includes an injunction, meaning Qilu accepted legally enforceable restrictions. This structure gives Theravance stronger enforcement tools than a private settlement alone would provide.
Court-ordered, not just settledTheravance secures injunction without contested litigation risk
For Theravance, the consent judgment represents a near-optimal outcome: injunctive relief protecting YUPELRI® market exclusivity was obtained in under 100 days, without the cost, uncertainty, or validity risk of full patent litigation. With seven patents asserted, a contested proceeding would have created significant IPR exposure. The agreed injunction forecloses Qilu’s immediate U.S. market entry while preserving Theravance’s patent portfolio intact.
Injunction secured, portfolio intactQilu accepts injunction — market entry deferred
By consenting to the judgment and injunction, Qilu accepted restrictions on U.S. commercialisation of its revefenacin product. The public record does not confirm whether a future licensed entry date was negotiated as part of the arrangement — which is common in pharmaceutical consent judgments but cannot be asserted here. Qilu retains the ability to re-enter the market consistent with whatever terms were privately agreed or upon patent expiry.
Entry deferred; private terms unknownYUPELRI® exclusivity reinforced across a layered patent estate
The enforcement of seven patents in a single action signals a deep, layered IP strategy around revefenacin — covering the compound, formulations, and likely methods of use across application families filed from 2010 through 2023. For other generic manufacturers monitoring YUPELRI®, this outcome raises the practical cost of any challenge: Theravance has demonstrated willingness to litigate and ability to secure rapid injunctive relief. Any ANDA filer for revefenacin products should conduct thorough FTO analysis across all seven patent numbers.
High barrier for generic entryFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Theravance Biopharma R & D IP, LLC | Company | Biopharmaceutical IP holding entity — holder of 7 revefenacin (YUPELRI®) patentsSearch in Eureka ↗ |
| Defendant | Qilu Pharmaceutical Co., Ltd. | Company | Qilu Pharmaceutical Co., Ltd. — Chinese generic pharmaceutical manufacturerSearch in Eureka ↗ |
| Plaintiff counsel | Eric G. Soller | Attorney | Counsel for Theravance Biopharma R & D IP, LLCSearch in Eureka ↗ |
| Plaintiff law firm | PIETRAGALLO GORDON ALFANO BOSICK & RASPANTI, LLP | Law Firm | Representing Theravance Biopharma R & D IP, LLCSearch in Eureka ↗ |
| Defendant counsel | KELSEY HUGHES-BLAUM | Attorney | Counsel for Qilu Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Defendant law firm | Taft, Stettinius & Hollister LLP | Law Firm | Representing Qilu Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Presiding judge | Judge KAI N. SCOTT | Judge | Pennsylvania Western District CourtSearch in Eureka ↗ |
Official order — verbatim text
The verdict text — ‘STIPULATION AND ORDER CONSENT JUDGMENT AND INJUNCTION ENTERED AS OUTLINED HEREIN’ — reflects a fully agreed disposition rather than any judicial finding on the merits of infringement or validity. The injunction component is particularly significant: it means the court entered enforceable prospective relief against Qilu, not merely a record of dismissal. The phrase ‘as outlined herein’ indicates the order incorporates specific agreed terms, which may include entry-date provisions or royalty arrangements not visible in the public docket. No invalidity findings were made, leaving all seven asserted patents presumptively valid.
US8541451B2 and 6 further patents — revefenacin inhalation solution (YUPELRI®)
The seven asserted patents collectively protect revefenacin — a once-daily, long-acting muscarinic antagonist (LAMA) delivered via nebulizer — which is the active ingredient in YUPELRI®, approved by the FDA for maintenance treatment of COPD. Application numbers span from US12/835964 through US18/199812, indicating filings from approximately 2010 through 2023. This breadth suggests the estate covers the core compound, formulation specifics, methods of treatment, and potentially manufacturing processes — a classic layered pharmaceutical patent strategy designed to extend effective exclusivity.
For competitors and generic manufacturers, the seven-patent stack creates a formidable clearance challenge. Each patent represents an independent validity and infringement analysis, and challenging all seven simultaneously in IPR proceedings would require substantial investment with no guarantee of success across the full portfolio. The most recently filed application (US18/199812, issued as US11858898B2) suggests active portfolio prosecution continued well after the product’s FDA approval, a pattern consistent with Theravance’s intent to maintain durable exclusivity. Any product developer working in nebulized LAMA or COPD inhalation therapy should treat this estate as a high-priority FTO target.
Should your COPD inhalation product be cleared against US8541451B2 and related patents?
Any company developing, manufacturing, or seeking to commercialise a nebulized muscarinic antagonist for COPD — particularly revefenacin-based formulations or structurally analogous compounds — faces material infringement risk from Theravance’s seven-patent revefenacin estate. This case demonstrates that Theravance actively monitors and enforces its portfolio: it filed suit within months of a perceived threat and secured injunctive relief in under 100 days. R&D teams working on next-generation COPD nebulizer therapies should commission FTO analysis before IND filing, not at the NDA stage.
PatSnap Eureka’s FTO Search Agent can map your compound or formulation against each of the seven asserted patent families simultaneously, flagging claim-level overlap and identifying design-around opportunities. Eureka’s patent landscape tools can also surface the full Theravance revefenacin prosecution history, including continuation filings and claim amendments, giving your IP team a complete picture of what is — and is not — covered. Start with a structured FTO query across all seven patent numbers to baseline your freedom to operate before committing to clinical development.
Run a freedom-to-operate analysis on US8541451B2 to assess your product’s exposure
Run FTO in Eureka →Similar COPD and nebulized LAMA patent infringement cases
Explore related pharmaceutical patent infringement cases involving nebulized COPD therapies and muscarinic antagonist compounds in U.S. district courts.
What this case signals for the COPD nebulizer IP landscape
A seven-patent consent judgment in 97 days is a strong signal of IP leverage — and a warning to other revefenacin ANDA filers.
Layered patent estates accelerate consent — challengers face compounding risk
Asserting seven patents simultaneously raises the stakes for any generic challenger: even a strong invalidity argument against one or two patents still leaves exposure across the remaining claims. This dynamic consistently drives early resolution in ANDA-adjacent pharmaceutical patent cases. Theravance’s portfolio depth was itself a negotiating lever.
Consent injunctions are harder to unwind than private settlements
Because the injunction here is court-ordered, Qilu cannot simply walk away if commercial circumstances change. Modification requires a court motion and a showing of changed circumstances. IP teams tracking generic competition for YUPELRI® should note that this order creates a durable enforcement posture that extends beyond typical settlement agreements.
Theravance v Qilu — key questions answered
Theravance Biopharma R&D IP, LLC asserted seven U.S. patents: US8541451B2, US11008289B2, US9765028B2, US11858898B2, US11691948B2, US10550081B2, and US11484531B2. All relate to revefenacin, the active ingredient in YUPELRI® (revefenacin) inhalation solution, a once-daily nebulized LAMA approved for COPD maintenance therapy.
The case was resolved via a stipulated consent judgment and injunction entered by Judge Kai N. Scott in the Western District of Pennsylvania on September 23, 2024 — 97 days after filing. The case was dismissed per the consent order. The specific terms of the injunction, including any licensed entry date or royalty provisions, are not publicly disclosed in the docket record.
By consenting to the judgment and injunction, Qilu Pharmaceutical accepted legally enforceable restrictions on U.S. commercialisation of its revefenacin inhalation product. The injunction is a court order, not merely a private agreement, meaning violation could result in contempt proceedings. Whether the order includes a negotiated future market-entry date is not confirmed in the public record.
The 97-day resolution is notably fast for a seven-patent pharmaceutical infringement action. This pace typically suggests pre-litigation negotiations were already advanced, or that the parties reached agreement quickly after service. The breadth of Theravance’s patent portfolio — seven patents covering a single drug product — likely created strong incentive for early resolution, as a contested proceeding would expose Qilu to significant injunctive risk across multiple independent patent claims.
YUPELRI® (revefenacin) is a once-daily, long-acting muscarinic antagonist (LAMA) delivered via nebulizer, approved by the FDA for COPD maintenance treatment. The seven asserted patents reflect a layered IP strategy common in branded pharmaceuticals: filings from approximately 2010 through 2023 cover the core compound, specific formulations, inhalation solution compositions, and methods of treatment, creating staggered patent expiries that extend effective market exclusivity beyond any single patent’s term.
PatSnap Eureka searches patents and litigation data to answer instantly.